Gravier Pierre's Insider Trades & SAST Disclosures
Gravier Pierre's most recent trade in PTC Therapeutics Inc was a trade of 1,168 Common Stock done at an average price of $50.1 . Disclosure was reported to the exchange on Feb. 19, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Gravier Pierre.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 50.10 per share. | 19 Feb 2025 | 1,168 | 75,603 (0%) | 0% | 50.1 | 58,512 | Common Stock |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 50.12 per share. | 19 Feb 2025 | 1,167 | 74,436 (0%) | 0% | 50.1 | 58,495 | Common Stock |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 56,250 | 56,250 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 22,500 | 76,771 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 34.02 per share. | 16 Jul 2024 | 2,269 | 53,531 (0%) | 0% | 34.0 | 77,200 | Common Stock |
| Cassava Sciences Inc | Pierre Gravier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Gravier Pierre | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 47,500 | 47,500 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 19,000 | 52,700 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 3,100 | 55,800 (0%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Gravier Pierre | CHIEF FINANCIAL OFFICER | Purchase of securities on an exchange or from another person at price $ 25.81 per share. | 12 Dec 2023 | 7,700 | 33,700 (0%) | 0% | 25.8 | 198,736 | Common Stock |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2023 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2023 | 26,000 | 26,000 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges